+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
MyoKardia Inc - logo

MyoKardia is a clinical stage biopharmaceutical company that develops therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, a small molecule that is in three Phase I clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Cardiovascular Collaboration and Licensing Deals 2016-2023 - Product Thumbnail Image

Cardiovascular Collaboration and Licensing Deals 2016-2023

  • Report
  • October 2023
  • 300 Pages
  • Global
From
From
From
From
From
From
From
Dilated Cardiomyopathy - Pipeline Insight, 2020 - Product Thumbnail Image

Dilated Cardiomyopathy - Pipeline Insight, 2020

  • Clinical Trials
  • September 2020
  • 67 Pages
  • Global
From
Hypertrophic Cardiomyopathy - Pipeline Review, H2 2020 - Product Thumbnail Image

Hypertrophic Cardiomyopathy - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 102 Pages
  • Global
From
Atrial Fibrillation - Pipeline Review, H2 2020 - Product Thumbnail Image

Atrial Fibrillation - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 134 Pages
  • Global
From
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2020 - Product Thumbnail Image

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 631 Pages
  • Global
From
Dilated Cardiomyopathy - Pipeline Review, H2 2020 - Product Thumbnail Image

Dilated Cardiomyopathy - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 66 Pages
  • Global
From
MyoKardia Inc - Strategic SWOT Analysis Review - Product Thumbnail Image

MyoKardia Inc - Strategic SWOT Analysis Review

  • SWOT Analysis
  • July 2021
  • 35 Pages
From
  • 18 Results (Page 1 of 1)
Loading Indicator